CMMB vs. XBIT, ZURA, IVA, RENB, ENTA, TNYA, ELUT, NVCT, MIST, and IGMS
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include XBiotech (XBIT), Zura Bio (ZURA), Inventiva (IVA), Renovaro (RENB), Enanta Pharmaceuticals (ENTA), Tenaya Therapeutics (TNYA), Elutia (ELUT), Nuvectis Pharma (NVCT), Milestone Pharmaceuticals (MIST), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry.
Chemomab Therapeutics vs.
Chemomab Therapeutics (NASDAQ:CMMB) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
XBiotech received 299 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 64.29% of users gave Chemomab Therapeutics an outperform vote.
Chemomab Therapeutics currently has a consensus target price of $7.50, indicating a potential upside of 267.65%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than XBiotech.
Chemomab Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.
Chemomab Therapeutics has higher earnings, but lower revenue than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
XBiotech's return on equity of -15.99% beat Chemomab Therapeutics' return on equity.
In the previous week, XBiotech had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.87 beat XBiotech's score of 0.09 indicating that Chemomab Therapeutics is being referred to more favorably in the media.
46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 33.1% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
XBiotech beats Chemomab Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMMB) was last updated on 2/1/2025 by MarketBeat.com Staff
